Endometrial Mixed Cell Adenocarcinoma

• CLINICAL_TRIALS trial_result · 2025-09-23
  Clinical Trial Update: Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone [Phase 2]

  Phase 2 trial in recurrent or refractory endometrial cancer evaluating Olaparib with Durvalumab, Cediranib with Durvalumab, Olaparib with Ca…

• CLINICAL_TRIALS trial_result · 2025-03-18
  Clinical Trial Update: Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer [Phase 3]

  Phase 3 trial evaluating adding pembrolizumab to paclitaxel and carboplatin for stage III-IV or recurrent endometrial cancer.

• CLINICAL_TRIALS trial_result · 2025-01-08
  Clinical Trial Update: Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer [Phase 2]

  Phase 2 clinical trial evaluating the combination of Onapristone and Anastrozole for refractory hormone receptor-positive endometrial cancer…

• CLINICAL_TRIALS trial_result · 2020-07-14
  Clinical Trial Update: Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer [Phase 2]

  Phase 2 trial evaluating cabozantinib S-Malate in recurrent or metastatic endometrial cancer has completed and results have been posted.

• CLINICAL_TRIALS trial_result · 2020-03-06
  Clinical Trial Update: Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer [Phase 2]

  Phase 2 trial evaluating copanlisib in persistent or recurrent endometrial cancer has completed with posted results.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.